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Monoclonal antibodies (mAbs) are highly specific antigen binding proteins that are used 
as biological reagents, therapeutics, and in rapid diagnostics. While mAbs have extensive potential 
applications, their means production for small molecules and conformationally specific peptides 
is difficult. Here, we use a method of mAb production in which we pair conjugate virus-like 
particle (VLP) vaccine with hybridoma technology to produce high-affinity mAbs against three 
classes of molecules 1) fentanyl derivatives, 2) SARS-CoV-2 peptides, and 3) α-amanitin and 
microcystin cyclic peptide toxins. We successfully produced broad and derivative-selective mAbs 
against eight fentanyl derivatives. We also showed early signs of success targeting neutralizing 
and mutant SARS-CoV-2 peptides with conformational specificity using a heterologous prime-
boost strategy. Lastly, we produced high affinity mAbs for both α-amanitin and microcystin, two 
highly toxic cyclic peptides. The early success of mAb production against the variety of targets 
presented in this thesis shows the viability and exceptional versatility of conjugate VLP vaccines 






















Monoclonal antibodies (mAbs) are immune cell derived proteins that have been at the 
forefront of biomedical research over the past 40 years. Their unique characteristics give them the 
potential to create cheap, fast, and accurate diagnostics as well as novel therapeutics. MAbs are 
identical immunoglobulins derived from the same clonal cell line that bind a unique epitope. They 
have shown tremendous promise as both diagnostics and clinical therapies due to their high 
specificity, strong antigen binding affinity, and relatively low cost to synthesize in large 
quantities.1, 2 Currently, their uses range from home pregnancy and drug tests to the clinical 
diagnosis and treatment of a variety of cancers, infectious diseases and autoimmune disorders.3, 4 
While mAbs hold the potential to bind a huge variety of antigens, allowing them countless 
potential applications, the biosynthetic process of mAb development poses limitations on 
acceptable antigen targets. This process relies on the ability of animal immune systems to produce 
high affinity immunoglobulin G (IgG) against the antigen of interest. Some antigens (including 
certain viral proteins) are naturally very immunogenic helping this immune response to occur, 
however others such as small molecule haptens and carbohydrates lack this ability. There are 
multiple immunological processes that help initiate this strong humoral response including uptake 
and presentation of the antigen by antigen presenting cells (APCs), engagement of the compliment 
cascade, proinflammatory CD4+ T cell response, and effective B cell receptor (BCR) crosslinking.5 
One way to overcome the limitations of some antigens is by use of a conjugate vaccine platform 
such as virus-like particles (VLPs), which are capable of activating these immunological 
processes. 
VLPs are immunogenic protein nanoparticles derived from bacteriophage that can be 





interest to our work, VLP Q and PP7, originate from Leviveridiae bacteriophage. They have 
multiple characteristics that allow them to engage each previously stated immunological process 
needed to activate humoral immunity. First, they are able to activate APCs through packaged 
mRNA, a ligand for TLR7 and TLR8 that when bound initiate antigen presentation and 
proinflammatory cytokine responses.5, 6 Since VLPs are proteins, they are also capable of major 
histocompatibility complex (MHC) class II presentation, which is necessary for B cell activation 
and affinity maturation.7 Their highly repetitive structure is also necessary for BCR cross linking 
which engages the classical pathway of the compliment cascade and facilitates B cell activation.5 
Lastly, Qβ and PP7 are roughly 28 nm in diameter which allows them to drain into the lymph 
nodes, increasing B cell exposure to antigens8 and resulting in IgG production and affinity 
maturation. VLPs are able to confer this immunogenicity to molecules covalently attached to them. 
We hypothesize based on the high-quality antibodies that result from conjugate VLP vaccines that 
this platform could be an ideal method of initial animal immunization with the ultimate goal of 
mAb discovery. 
In addition to helping establish a proof of concept for the viability of VLP vaccines in the 
development of mAbs, each target molecule presented in this thesis, diverse in structural 
classification, poses a public health risk that the production of mAbs stands to help alleviate. Small 
molecule fentanyl and its derivatives are synthetic opioids that have been the leading cause of 
overdose deaths in the United States since 2015.9 Some of these derivatives still lack proper 
diagnostics tools, underscoring a need for the diagnostic mAb development and, if humanized, 
could serve as a passive biological therapy for overdose victims. SARS-CoV-2, the viral agent 
responsible for the COVID-19 pandemic, has resulted in millions of deaths worldwide.10 There is 





fast and inexpensive diagnosis. Finally, cyclic peptide microcystin-LR and α-amanitin are natural 
products found in freshwater cyanobacteria and some species of mushrooms, respectively. Both 
are toxic to humans and animals and have a high risk for contamination of drinking and agricultural 
water supplies, creating a need for the development of a fast-acting field diagnostic to test for the 
presence of these toxins.11, 12 While each of these targets differ considerably from one another, 
they all pose a significant threat to human health that can be at least partially alleviated via mAb 
applications. 
 
In this project, we overcome the limitations presented by certain target molecules by 
pairing conjugate VLP vaccine platforms with hybridoma technology in order to discover mAbs 
against designer drug haptens, viral peptides, and toxins (Scheme 1). Chemically ligated PP7 and 
Qβ conjugate VLP vaccines were generated against a panel of fentanyl derivatives, several SARS-
CoV-2 spike protein peptides, and the toxins microcystin-LR and α-amanitin. Additionally, we 
genetically engineered PP7 VLPs to display several more SARS-CoV-2 spike protein peptides. 
We immunized mice with each of these vaccines, as well as conducted various combination 
immunizations between the SARS-CoV-2 peptide VLPs and the unconjugated whole protein. 
Once high affinity IgG producing B cells were derived, hybridoma technology was used to 
electrofuse solenocyte B cells with immortal myeloma derived from murine lymphocytes by our 






collaborators at Centers for Disease Control and Prevention (CDC, Scheme 1). The resultant 
hybridomas created clonal lines capable of producing a large supply of mAbs. Each clone was 
screened for antigen specificity and multiple positive clones were discovered for each target. 
Biophysical characterization of antigen specific clones was determined describing binding affinity, 
and IgG isotype. Antibody function was further explored by determining selectivity, cross 
reactivity of fentanyl and toxin mAbs to similar antigens and neutralization ability of SARS-CoV-
2 mAbs. The success of mAb production against our array of antigenic targets as well as the various 
immunization strategies presented in this thesis, shows the viability and exceptional versatility of 


































Monoclonal Antibodies, Virus-like Particles, and Hybridoma Technology 
Monoclonal Antibodies (mAbs) are identical immunoglobulins that are produced from 
clonal plasma cells which share a unique parent B cell. Kohler and Milstein were awarded the 
Nobel prize in 1984 for their development of a method to biosynthesize mAbs.13 Since this 
discovery, mAbs have shown tremendous promise as both diagnostics and therapeutics due to their 
high specificity, strong antigen binding affinity and relatively low cost to synthesize in large 
quantities.1, 2 Their value was first seen in bioassay applications, where they are now commonly 
used as reagents.14 The development of mAb humanization methods unlocked their potential in a 
clinical setting. The first FDA approved mAb for clinical use was designed for the prevention of 
kidney transplant rejection.15 Now, there are over 100 approved mAbs for use as therapies against 
cancers, infectious diseases, auto immune diseases and more.16 Monoclonal antibody therapeutics 
are also extremely profitable; their annual sales are expected to reach over $130 billion by 2023.17  
The utility of mAbs comes from their ability to bind an epitope, the region on the antigen 
recognized by the antibody, with a very high specificity and affinity. The development of novel 
mAbs first requires the synthesis of a vaccine for the antigen of interest followed by animal 
immunization, plasma cell extraction via splenectomy and finally, plasma cell fusion with 
myeloma to create immortal cell lines selected based on its ability to bind the immunogen.18 While 
this is initially a labor intensive process, once the clonal cell line for an mAb is produced, its mass 
production is relatively simple and cost effective.18  
The first difficulty that arises in the discovery of mAbs is the development of a vaccine for 
the antigen of interest. Despite the ability of antibodies to bind a vast array of epitopes, initiating 





challenging. While many antigens, including multivalent viral and bacterial proteins, are naturally 
very immunogenic, others such as small molecules and carbohydrates lack the ability to activate 
the critical components of humoral immunity necessary for high affinity immunoglobulin G (IgG) 
production.6 One way to overcome the limitations of some antigens is by use of a conjugate vaccine 
platform such as virus-like particles (VLPs), which are capable of activating these immunological 
processes.  
Virus-like particles are non-infectious protein nanoparticles that mimic viral structures and 
can be genetically engineered or covalently modified to present an antigen of interest.19 Chimeric 
VLPs are a type of VLP that use a self-assembling recombinant viral envelope protein linked to a 
display molecule thus allowing a limitless versatility of antigens capable of being presented by a 
VLP. Chimeric VLPs have multiple characteristics that make them an ideal vaccine platform for 
antibody production (Figure 1). Since VLPs are proteins, they are capable of binding major 
histocompatibility complex (MHC) class II unlike non-protein antigens.7 This is a vital component 
of antigen presentation that allows for CD4+ T cell activation, thereby promoting B cell activation 
and affinity maturation through IL-6 and IL-21 cytokine interactions.6, 20 VLPs also spontaneously 
self-assemble in induced E. coli cells which allows them to package free floating mRNA.5 This 
mRNA is a ligand for Toll-like receptor (TLR) 7 and TLR8 which help engage the APCs necessary 
for T cell priming and B cell activation.6 The size and shape of VLPs also plays a significant role 
in their immunogenicity. VLPs PP7 and Q are typically ~28nm in diameter, allowing them to 
drain into lymph nodes independently of cellular transport which has been shown to increase 
antigen exposure to B cells.8 VLPs also have highly repetitive structures. This helps activate B 
cells both directly through cross linking of BCRs, especially immunoglobulin M (IgM), and 





facilitates B cell activation.5 The variety of mechanisms by which VLPs interact with humoral 
immunity allows them to both elicit IgG production and promote affinity maturation. We 
hypothesize that the high-affinity antibodies that result from conjugate VLP vaccines will make 













Two commonly used VLP platforms are Qβ and PP7 (Figure 2). They are both icosahedral, 
nonenveloped VLPs that are recombinantly derived from single-stranded RNA bacteriophages.21, 
22 Both VLP capsids are assembled from 180 repeating coat protein units that are stabilized through 
noncovalent interactions as well as inter-subunit disulfide bonds.23-25 These strong noncovalent 
and covalent interactions allow Qβ and PP7 to be chemically modified under a variety of 
conditions without losing the integrity of the protein structure. Each coat protein has seven lysine 
residues and a terminal amine that serve as nucleophiles in bioconjugation reactions involving N-
hydroxysuccinimide (NHS) and subsequent chemical modification, making them great candidates 
for multivalent small molecule and carbohydrate antigen presentation. Additionally, both VLPs, 
when subject to genetic modification, have been shown to successfully to display short surface 
peptides at either the C- or N-terminus.26, 27 Both Qβ and PP7 provide exceptional VLP vaccine 
platforms due to their versatile antigen presentation abilities. 
A B 





 Once a vaccine against the antigen of interest has been successfully made, an effective 
immunization schedule and adjuvant must be chosen to help bolster murine immune responses. 
Adjuvants are substances that can be added to a vaccine to increase overall effectiveness while 
decreasing the number of doses required to obtain a desired immune response.28 Adjuvants are 
able to accomplish this in a variety of ways. Freud’s Adjuvants and TiterMaxⓇ Gold (TMX) does 
this by the creation of an oil in water emulsion which creates both an antigen depot and the site of 
injection and causes retention of the antigen in the lymphoid tissue.29, 30 As discussed previously, 
localization in the lymph nodes is a vital to antigen exposure to B cells. Another mechanism that 
some adjuvants utilize is the activation of innate immune cells that increase B cell activity through 
costimulatory molecules. α-galactosylceramide is an invariant natural killer T cell (iNKT) agonist 
that accomplishes this by binding CD1d receptor on iNKT cells.31, 32 These cells in turn produce 
large amounts of INF-γ, a cytokine that helps stimulate adaptive immune responses.6 Both TMX 
and NKT agonist adjuvants have been shown to encourage antibody immune responses and 
therefore are ideal candidates to be used during vaccination for our method of mAb discovery.  
 Inducing mouse immune systems to generate high affinity antibodies against the antigen 
of interest is only half the battle. Once achieved, the B cells that make those antibodies must be 
extracted and fused with myeloma (immortal mouse lymphocytes) in order to create a hybridoma 
which can make an immortal line of IgG-secreting clones.18 Once the hybridoma are generated, 
each cell must be separated, and its secreted antibodies tested for antigen specific IgG production.18 
To do this our collaborators at CDC use a high throughput hybridoma screening method in which 
the cells are suspended in a semi-solid media containing a colorimetric substrate that identifies 
IgG secretion.33 Automated selection of the positive colonies is performed using a ClonePix 





Conjugate VLP immunization paired with hybridoma technology was used to create high 
affinity mAbs against three distinct sets of molecules. Fentanyl and its derivatives are small 
molecules that are not naturally immunogenic; by conjugating them with a VLP we were able to 
produce strong humoral immune responses. While the SARS-CoV-2 spike protein is highly 
immunogenic, by conjugating spike protein peptides to VLPs we were able to generate an immune 
response against those specific peptides, allowing us to generate antibodies against known 
neutralizing epitopes as well as high-profile mutant epitopes. Microcystin-LR and α-amanitin are 
cyclic peptides that have a high toxicity; by conjugating them with a VLP we are able to increase 
their immunogenicity while decreasing toxicity. Each of these groups of molecules also pose a 
threat to human health that high affinity mAbs have the potential to help alleviate.  
 
Fentanyl Derivatives 
 Fentanyl is a synthetic opioid derivative used clinically as an anesthesia and as an analgesic 
to treat post-operative, acute or terminal pain. After first being synthesized in 1960, it was hailed 
by clinicians for its high potency, allowing it to adequately treat pain in very small doses.34 In fact, 
to this day fentanyl and its derivatives are some of the most active known mu-opioid receptor 
agonists.35 Fentanyl has a nearly 1000x higher potency than morphine and its analogue carfentanil 
has a nearly 10,000x higher potency (Table 1). This high potency, while clinically valuable, has 
made fentanyl popular target for illicit drug use.   
Fentanyl is responsible for a rapidly increasing number of overdose deaths each year. 
Fentanyl and its derivatives have become the leading cause of overdose deaths in the United States 
resulting in 60,000-80,000 deaths each year since 2016.9, 36 This increase can be attributed to both 





taking it as it is over 7x more lethal than heroin (Table 1). In addition to intentional fentanyl use, 
it has also emerged on the black market as a filler in other illicit narcotics like heroin and cocaine.37 
Unintentional fentanyl consumption by individuals taking other drugs is responsible for over half 
of overdose deaths today.38, 39 
Table 1. Relative opioid potencies and lethalities. All measurements taken in Sprague-Dawley rats 
after intravenous administration and determined by similar methods. 




Morphine 3.2140 22340 1 1 
Heroin 0.12941 22.542 25 10 
Fentanyl 0.003943 3.0535 823 73 
Carfentanil 0.000444 3.3935 8025 67 
 
 Monoclonal antibodies have the potential to help curb the current fentanyl epidemic in a 
variety of ways. First, we hypothesize they can be used in immunoassay diagnostics to rapidly, 
reliably, and inexpensively detect and distinguish fentanyl and its analogues in circulation from 
other opioids. These diagnostics could help medical professionals better treat overdose victims and 
trace its origins. The elimination half-life of fentanyl in the blood stream is 90-360 minutes which 
is significantly longer than that of other common narcotics such as heroin which has a half-life of 
only 9-22 minutes.45, 46 The elimination half-life of naloxone, the most commonly used overdose 
reversal medication, is only 30-120 minutes, making repeat fentanyl overdoses after initial 
treatment a substantial concern.47 As a result, knowing fentanyl was involved in an overdose 
significantly impacts the administration schedule of reversal medication. Since compliance in 
overdose situations can be very low and other drugs are often laced with fentanyl without the user’s 
knowledge, diagnostics that can quickly test for low concentrations of fentanyl in blood or urine 





In addition to use in diagnostics, fentanyl binding mAbs have also shown promise as a 
biological therapy to treat overdose victims. A recent study by Smith, et al. (2019)48 found that 
mAbs developed against fentanyl and carfentanil decreased symptoms in mice associated with 
fentanyl intoxication as well as increased the LD50 – the median lethal dose. The elimination half-
life of these mAbs in the blood was also shown to be several days, significantly longer than that 
of fentanyl and naloxone.48 The mechanism by which mAbs and naloxone can combat opioid 
intoxication also differ greatly. Naloxone competitively binds opioid receptors, while mAbs 
neutralize and opsonize fentanyl thereby preventing it from binding the receptors and labeling it 
for degradation in the blood stream. As a result, it is possible that these two treatments could be 
combined, with naloxone being used as the fast-acting component and mAbs providing long 
lasting protection against repeat overdoses. 
 Toxicity and lack of immunogenicity of these fentanyl derivatives makes producing 
potentially lifesaving mAbs difficult. In this study, we overcame these limitations by conjugating 
eight different fentanyl immunogens with alkyne linkers to PP7 VLPs using the Copper catalyzed 
azide alkyne cycloaddition (CuAAC) reaction. This strategy uses the VLP to engage humoral 
immunity while creating specificity towards the fentanyl derivatives. The vaccines were then 
immunized into BALB/c mice until optimal IgG production was elicited (usually 7-9 weeks post 
prime). Hybridoma were then created through electrofusion of the resultant B cells with murine 
myeloma. The mAbs derived from the hybridomas were then screened for cognate antigen 
specificity, cross reactivity with the other derivatives for diagnostic purposes, and cross reactivity 
to naloxone for therapeutic purposes. Ultimately, we produced 14 mAbs with unique binding 
patterns to the eight derivatives. These mAbs have the ability to address weaknesses in current 







 SARS-CoV-2 is an enveloped RNA virus that causes mild to severe respiratory infections, 
a disease known as COVID-19.49  As of April 2021 COVID-19 is attributed to nearly 3 million 
deaths worldwide and over 500,000 in the united states alone.10 The World Health Organization 
(WHO) declared COVID-19 a global pandemic in March 2020.50 Since then, restrictions used to 
slow the spread of the virus have also crippled world economies and left millions out of work. 
There has been an urgent need for quality reagents, diagnostics, and therapeutics all of which can 
be obtained through mAb production. Specifically, there is a need for mAbs that bind known 
neutralizing epitopes and epitopes containing new emerging mutations.  
 The SARS-CoV-2 virus contains an ectodomain known as the spike protein. The spike 
protein is an important element of SARS-CoV-2 pathology as it is responsible for binding 
angiotensin-converting enzyme 2 (ACE2) which allows it to gain entry into human epithelial 
cells.51 The receptor binding domain (RBD) is the portion of the spike protein that makes physical 
connections to the ACE2 receptor.52 As a result, this is an important region to target for the creation 
of neutralizing antibodies. In fact, a large percentage of neutralizing mAbs isolated from infected 
humans bind the RBD.53-55 A few have also been isolated that bind to the N-terminal domain 
(NTD) of the spike protein.55, 56 Based on these findings, it is clear that certain epitopes on the 
spike protein are very important to neutralizing antibody development. 
 In order to target these known neutralizing epitopes, we created a heterologous prime-boost 
strategy in which we primed with PP7 conjugated to the linear peptide in order to create a targeted 
immune response. We then boosted with whole protein RBD to ensure the affinity matured 
antibodies bound the peptide in its native conformational state. To create the VLP-peptide vaccines 





the peptide nucleic acid sequence at the C-terminus. In the second strategy, the assembled PP7 
particles were conjugated with the peptides modified with an alkyne linker using the CuAAC 
reaction. We tried both the VLP-peptide immunizations individually and with cocktails containing 
different VLP-peptide conjugates. The cocktail strategy allows for targeting of multiple epitopes 
in a single vaccination. The preliminary results are promising that we were able to direct the 
polyclonal immune response towards our peptides of interest. 
 In addition to targeting known neutralizing epitopes we also targeted peptides containing 
important mutations. The Y453F mutation is a high profile mutation in the RBD known to allow 
transmission between minks and humans.57 Y453 is an important amino acid since it directly 
interacts with the ACE2 receptor helping viral entry into cells.51, 58 The effect of this mutation on 
binding of previously effective neutralizing mAbs has been tested. These studies have shown that 
this mutation decreases the neutralizing ability of multiple of these mAbs.59-61 In this study, we 
attempt to make mAbs that differentially bind either to Y453F mutant or the wild type. To do this 
we tried two different heterologous prime-boost strategies based on competing hypotheses. In the 
first, we primed with VLP-peptide to try to direct the initial immune response towards the peptide, 
then boosted with RBD to ensure affinity maturation occurs to the peptide in its native 
conformational state.  In the second we primed with RBD to select for germline B cells that bind 
the RBD then boost with peptide to mature only the fraction that bind the peptide of interest.  
 To test for peptide and confirmational specificity we used two types of ELISAs. With the 
first the whole RBD protein was plated to test for conformational specificity; however, this strategy 
does not confirm binding to the peptide of interest. In the second strategy biotinylated peptide was 
plated on streptavidin plates to test for peptide specific response. Though this strategy ensures only 





and missing ones that need conformational specificity. We found that the RBD prime with peptide 
boost did a better job at directing the long-term immune response towards the peptide. Ultimately, 
we were able to isolate mAbs with both wild type and mutant RBD preference.  
 
 
α-Amanitin and Microcystin toxins 
α-Amanitin and microcystin LR are both hepatotoxins that are naturally produced by 
environmental agents. α-Amanitin is produced by several species of mushroom (including the 
death cap mushroom), and microcystin is synthesized by fresh water cyanobacteria.11,12 When 
ingested, α-Amanitin inhibits RNA polymerase II, resulting in inefficient protein synthesis, cell 
necrosis, and ultimately liver and kidney failure.62 Microcystin LR similarly causes liver damage 
and death, however its mechanism of action involves induced apoptosis from oxidative stress 
placed on the cell due to interactions between microcystin and protein phosphatases.63 Both of 
these toxins have the potential to contaminate water supplies that provide irrigation to crops in 
large scale farming and clean drinking water for high density populations. The development of a 
fast-acting field diagnostic to test for the presence of these toxins is crucial to ensure that supplies 
of water have not been naturally or artificially polluted with these toxins. 
 The high toxicity and lack of immunogenicity of these cyclic peptides makes producing 
mAbs for them difficult. In this study, we conjugated each toxin to the Qβ VLP using the CuAAC 
reaction. We used this conjugate vaccine platform to direct the humoral immune response in 
BALB/c mice. Once optimal antigen specific IgG titers were obtained the resultant B cells were 
used to create hybridoma using hybridoma technology. Using this method, we produced dozens of 
high affinity antigen specific clones for both α-amanitin and microcystin LR. These mAbs will be 





MATERIALS AND METHODS 
4.1 Transformation and Particle Expression 
To produce VLPs, BL21(DE3) chemically competent Escherichia coli cells were transformed 
using heat shock with either PP7 or Qβ bacteriophage derived coat protein pET plasmids 
containing a kanamycin resistance gene. The transformed cells were plated on positive-selection 
kanamycin containing agar to prevent non-transformed cell growth and incubated overnight at 
37oC. Single colonies chosen from the plates were added to 125 mL SOB broth starter cultures 
with kanamycin and incubated overnight at 37oC with shaking. Thirteen mL of starter culture broth 
was then added to each 1 L expression culture of kanamycin-containing SOB broth and incubated 
at 37oC with shaking until reaching an optical density of 0.9 (usually ~4 h). The cultures were then 
induced with β-D-1-thiogalactopyranoside (IPTG) and incubated overnight at room temperature 
with shaking to activate the lac operon controlling nanoparticle transcript. The cultures were 
pelleted by centrifugation the following day.  
 
4.2 Particle Purification and Characterization 
To purify the recombinant particles from the E. coli cells, the pellets were each dissolved in 0.1 M 
KPO4 buffer (pH 7.4) and lysed by sonication. The lysate was centrifuged, and the pellet containing 
insoluble cellular components removed. Excess ammonium sulfate was added overnight at 4 oC to 
the lysate to precipitate the proteins and centrifuged the following day to form a pellet. The pellet 
was then resuspended in 0.1 M KPO4 and the proteins separated from any remaining lipids by 
organic extraction using an equal volume of 1:1 chloroform: butanol. The recombinantly produced 
nanoparticles were then purified from other cell proteins using a sucrose gradient (10% to 40%). 





were then pelleted by ultracentrifugation and resuspended in 0.1 M KPO4. Purified particle 
concentration was determined by Bradford analysis using bovine serum albumin (BSA) standards 
and Coomassie brilliant blue. Particles were characterized using dynamic light scattering (DLS), 
fast protein liquid chromatography (FPLC) and liquid chromatography-mass spectrometry 
(LCMS) to determine particle diameter and monodispersity, purity, and molecular weight, 
respectively.  
 
4.3 Particle Modification 
Particle Modification by Chemical Ligation (Conducted by Asheley Chapman & Robert Hincapie) 
Chemically ligated particle modifications were conducted by Asheley Chapman and Robert 
Hincapie in the lab of Prof. M.G. Finn at Georgia Tech. PP7 particles were modified to display the 
fentanyl derivatives and RDM, FP and Y453F mutant SARS-CoV-2 peptides; the Qβ particles 
were modified to display the toxins. The VLPs were modified to display azides using NHS-ester 
azido-acetate linkers. Alkyne-labeled fentanyl derivatives, SARS-CoV-2 peptides and toxins were 
installed by copper catalyzed azide alkyne cycloaddition (CuAAC). Conjugates were purified by 
column chromatography and concentrated by centrifugation. Protein concentrations were 
determined by Bradford assay and characterization was confirmed by DLS, FPLC and LCMS 
(Appendix A,B,C).  
 
Particle Modification by Genetic Engineering (Conducted by Liangjun Zhao & Parisa Keshavarz-
Joud) 
Genetic particle modifications were conducted by Liangjun Zhao and Parisa Keshavarz-Joud in 





sequences were cloned into the PP7 plasmids. This allowed for C-terminus display of the linear 
peptides on each coat protein monomer resulting in multivalent peptide presentation on the 
assembled nanoparticle. Protein concentrations were determined by Bradford assay and 
characterization was confirmed by DLS, FPLC and LCMS (Appendix B).  
 
4.4 Immunization and B Cell Perfusion 
All animal studies were performed in compliance with the Georgia Institute of Technology 
Institutional Animal Care and Use Committee and all protocols followed National Institute of 
Health Guide for the Care and Use of Laboratory Animals Guidelines.  
 
Fentanyl Conjugate Vaccine Immunizations 
Six-week-old female BALB/c mice received initial bilateral subcutaneous immunizations on day 
0 and subsequent boosts on days 14 and 28. Each mouse received 100 µL total for each 
immunization containing 50 µg of conjugate vaccine in 0.1 M sterile KPO4 along with 500 ng of 
PBS-57 in 1 µL DMSO co-mixed immediately before injection. Mice selected for use in 
hybridoma development based on serum ELISA screening were given an additional boost with 
100 µL of 10 µg conjugate vaccine 3 days prior to harvesting spleens. The mice were bled by 
submandibular puncture at days 0, 14, 21, 28, 35, and when terminated (varies by vaccine due to 
scheduling conflicts). Mice selected for harvest were sacrificed using CO2 on day 35 (CF1, OMe`-
Fen), 43 (Fentanyl, NCF1, Acetyl Me-Fen, 3Me-Fen), or 53 (Fen13 and NCF2). Splenectomies 
were then performed and the B cells from the harvested spleens perfused using 20 mL of Iscove's 






SARS-CoV-2 Peptide Conjugate Vaccine Immunizations 
Six-week-old female BALB/c mice received initial bilateral subcutaneous immunizations of the 
VLP-peptide on day 0 and subsequent boosts of whole protein according to Table 1. Protein 
amounts per immunization are depicted in Table 1 according to initial conjugate vaccine 
administered with a total volume of 100 µL in 0.1 M sterile KPO4 for each. Mice were bled on day 
0, 32 (28 for each cocktail) and when terminated. Mice selected for harvest were sacrificed using 
CO2. Splenectomies were then performed and the B cells from the harvested spleens perfused 
using 20 mL of Iscove's Modified Dulbecco's Medium (IMDM) for hybridoma production by 
CDC. 
Table 1. SARS-CoV-2 immunization schedule. 
 
 
Amanitin and Microcystin Conjugate Vaccine Immunizations 
Six-week-old female BALB/c mice received initial bilateral subcutaneous immunizations of the 
VLP-peptide on day 0 and subsequent boosts on days 14, and 35. Each mouse received a 100 µL 
dose with 30 µg of conjugate VLP vaccine in 0.01 M KPO4 with no adjuvant. Mice selected for 





conjugate VLP vaccine in 0.01 M KPO4 with 500 ng of PBS-57 adjuvant mixed immediately 
before injection 3 days prior to splenectomy. The mice were bled on days 0, 7, 14, 21, 35, 42, 49, 
and 56 by submandibular bleed. Mice selected for harvest were sacrificed using CO2 on day 56. 
Splenectomies were then performed and the B cells from the harvested spleens perfused using 20 
mL of Iscove's Modified Dulbecco's Medium (IMDM).  
 
4.5 Serum ELISA 
Streptavidin ELISAs 
Serum antigen specific antibody binding was measured by streptavidin ELISAs. 1 µg/mL 
streptavidin in 0.1 M PBS was plated overnight at 4oC on high binding ELISA plates. The plates 
were then washed with 0.1 M PBS with 0.05% tween (PBST). One hundred µL of block casein 
was plated for 1 hour at room temperature with light shaking to prevent non-specific binding. The 
plates were subsequently washed with 125 µL PBST three times. Cognate biotinylated antigen was 
then plated at a concentration of 0.25 µg/mL in blocking buffer for 1 hour at room temperature 
with shaking. The plates were then washed again with PBST. To generate serum titers, 6 4x 
dilutions of each serum were plated in duplicate for 1 hour at room temperature then washed again. 
Secondary antibody goat anti-mouse total IgG HRP (1:2500 dilution) in blocking buffer was plated 
for 1 hour at room temperature. For the IgM and subclass ELISAs, anti-IgM, IgG1, IgG2a, IgG2b, 
or IgG3 HRP conjugates were plated instead of the total IgG HRP. The plates were once again 
washed. The plates were developed for 30 seconds using TMB and quenched using 2N H2SO4. 
The absorbance at 450 nm was measured by plate reader. Serum titers were generated using 







Serum antibody specificity to the VLP carrier, or antigen specificity to COVID peptides or Ecto 
whole proteins, were measured by protein ELISA. We plated 0.25 µg/mL protein in 0.1 M PBS 
overnight at 4oC on high binding ELISA plates. The plates were then washed with 0.1 M PBS with 
0.05% tween (PBST). One hundred µL of block casein was plated for 1 hour at room temperature 
with gentle shaking to prevent non-specific binding. The plates were subsequently washed with 
PBST. To generate serum titers, 6 4x dilutions of each serum were plated in duplicate for 1 hour 
at room temperature then washed again. Secondary antibody goat anti-mouse total IgG HRP 
(1:2500 dilution) in blocking buffer was plated for 1 hour at room temperature. The plates were 
once again washed. The plates were developed for 30 seconds using TMB and quenched using 2N 
H2SO4. The absorbance at 450 nm was measured by plate reader. Serum Titers were generated 
using sigmoidal regression analysis on GraphPad Prism of Log10 serum dilution versus 
absorbance. 
 
4.6 Hybridoma Development (Conducted at CDC) 
The hybridoma fusions were conducted by the Immunodiagnostics Development team at CDC. 
Perfused B cells were mixed with SP2-IL6 myelomas and the cells were fused by electric-field 
induced cell-to-cell fusion. The fused hybridoma were then plated into a semi-solid matrix 
containing CloneDetect and picked for IgG positivity through automated selection.  
 






Antigen specific antibody binding of hybridoma supernatant (containing secreted clonal IgG), was 
measured by streptavidin or protein ELISAs. Either 1 µg/mL streptavidin or 0.25 µg/mL of protein 
in 1x PBS was plated overnight at 4oC on high binding ELISA plates. The plates were then washed 
with 1x PBS with 0.05% tween (PBST). One hundred µL of casein blocking buffer was plated for 
1 hour at room temperature with gentle shaking to prevent non-specific binding. The plates were 
subsequently washed with PBST. For the streptavidin ELISAs, cognate biotinylated antigen was 
then plated at a concentration of 0.25 µg/mL in blocking buffer for 1 hour at room temperature 
with shaking. The plates were then washed with PBST.  Supernatant (100 µL) was plated directly 
onto the ELISA plate for 1 hour at room temperature. Secondary antibody goat anti-mouse total 
IgG HRP (1:2500 dilution) in blocking buffer was plated for 1 hour at room temperature. For the 
IgM and subclass ELISAs, anti-IgM, IgG1, IgG2a, IgG2b, or IgG3 HRP conjugates were plated 
instead of the total IgG HRP. The plates were once again washed. The plates were developed for 
30 seconds using TMB and quenched using 2N H2SO4. The absorbance at 450 nm was measured 
by plate reader. Serum Titers were generated using sigmoidal regression analysis on GraphPad 
Prism of Log10 serum dilution versus absorbance. 
 
Kd by BLI (Conducted at the CDC) 
Antibody affinity constants were determined by the ImmunoDiagnostics team at the CDC. Label-
free analysis of binding by biolayer interferometry (BLI) was performed for selected mAbs against 
their cognate antigen. The resultant data was analyzed to deduce direct binding affinities by the 
kinetic rate constants (1/Kads = kdis/kon, where 1/Kads = apparent equilibrium dissociation constant, 







RESULTS AND DISCUSSION 
5.1 Fentanyl Derivatives 
5.1.1. Fentanyl Derivative Selection and Structures 
 We chose to target eight different fentanyl derivatives for mAb production including six 
commonly found in illicit use (fentanyl, fentanyl 13a, carfentanil, 4MeO-Bu fentanyl, 3Me-
fentanyl, and acetyl αMe-fentanyl) and two metabolites that result from the breakdown of fentanyl 
in the body (norcarfentanil-1 and norcarfentanil-2). A recent study by Wharton, et al. (2021)64 
tested the efficacy of 19 commercially available immunoassays in detecting 30 common fentanyl 
derivatives. They found that while most were able to adequately detect a few compounds, none 
were capable of detecting a significant portion of the derivatives.64 Additionally, some derivatives, 
notably 3Me-fentanyl and 4MeO-Bu fentanyl, were poorly detected across all commercially 
available immunoassays tested. Based on the need depicted by Wharton and team we selected our 
eight fentanyl derivatives for mAb development (Figure 1).   
 The synthesis of the propargylated fentanyl derivatives for vaccination and the biotinylated 
derivatives with PEG linker used in ELISA analysis was conducted by Dr. Minghao Xu in the lab 
of Prof. M.G. Finn at Georgia Tech (Appendix A). All derivatives include amide, anilidine, 
piperidine, and alkylbenzene functional groups except norcarfenanil-1 and norcarfentanil-2 
(Figure 1). As metabolites that result from breakdown of fentanyl in the body, norcarfenanil-1 and 
norcarfentanil-2 increase in concentration over time after initial entrance of fentanyl into the body. 
This makes them valuable targets for blood and urine detection. Their small size and limited 
number of unique features, however, also poses a limit on the availability of unique epitopes for 





norcarfentanil-2 could be more difficult to elicit an optimal humoral immune response against than 




Each derivative also has an alkyne linker installed for bioconjugation to the reactive azide 
linkers on the PP7 VLP particles by copper catalyzed azide-alkyne cycloaddition (CuAAC 
reactions and vaccine conjugation performed by Dr. Asheley Chapman). Fentanyl, fentanyl 13a, 
norcarfentanyl-1, 4MeOBu fentanyl, and 3Me-fentanyl each have the linker installed at the 
alkylbenzene “tail” position of the molecule (Figure 1). Norcarfentanil-1, carfentanil, and acetyl 
αMe-fentanyl have the linker installed at the amide “head” position of the molecule (Figure 1). 
The orientation of the “tail” linker allows more exposure for the amide anilide head of the molecule 
Figure 1. Structure of fentanyl derivatives for vaccine conjugates. Amide (purple) functional groups represented 
in all derivatives except fentanyl 13a. Anilide (green), piperidine (blue), and alkyne linker (red) group represented in 






while the “head” linker allows more exposure for the core of the molecule. This has the potential 
to affect the presentation of the molecules to BCRs and therefore influence the epitopes selected 
for in antibody production. 
5.1.2. Immunization Strategy Optimization 
Before immunizing mice with all the derivative vaccines, an optimization experiment was 
performed using the fentanyl 13a vaccine to determine optimal duration, appropriate number of 
boosts, and most effective adjuvant. Though VLPs are considered to be self-adjuvating, we chose 
to explore the potential benefit of the iNKT agonist PBS-57 (NKT) and TiterMax (TMX) 
adjuvants. Hapten vaccines have the tendency to overwhelm immune responses with IgM, 
decreasing the amount of class switching to the coveted high affinity IgG.65, 66 Since both PBS-57 
and TiterMax have been shown to direct humoral immunity to IgG production, we hypothesized 
that they may help to avoid this unwanted IgM influx.29, 67 To test this hypothesis, we immunized 
BALB/c mice at week 0 with three immunization strategies: VLP-13a fentanyl vaccine alone 
(13a), 13a with the iNKT adjuvant (13a +NKT) and 13a with the TiterMax adjuvant (13a +TMX) 
(Figure 2A). The non-adjuvated group was boosted at weeks 2 and 4 and the adjuvated groups 
were boosted at week 6. All groups were then boosted again 3 days prior to termination and 
splenectomies were performed on week 13. 
 Serum ELISAs were conducted each week to determine antigen specific IgG antibody 
production (Figure 2B). All groups showed high titers (>104) beginning one week post initial 
immunization. Prior to week 6 the 13a +NKT group showed a slightly lower titer than the other 
groups, however, after the second immunization at week 6 it exceeded the other groups and had 
the highest titer upon termination, though the differences were not significant. These results show 





response. Though high titers were presented only one week post primary immunization, the 
ELISAs do not ensure high affinity antibody response, therefore it was determined that a 5-8-week 
immunization schedule with multiple boosts would be ideal to ensure adequate time for affinity 
maturation. 
 
Figure 2. Analysis of fentanyl 13a immunogenicity by adjuvant. (A) Immunization schedule for PP7-fent 13a 
vaccine without adjuvant (green), with NKT agonist PBS-57 (pink) and with TiterMax (blue) in BAB/c. (B) Anti-
fentanyl 13a IgG responses for each group measured by ELISA. Points represent mean and error bars are SEM (n=3 
per group). (C) IgG isotype responses at week 9 for each group measured by ELISA. (D) IgM responses for each 
group at weeks 2, 4, 9 and 13 measured by ELISA. (E) Total number of B cells resulting from spleen perfusion 
(blue), number of IgG clones that resulted from hybridoma fusion (purple) and number of antigen specific clones 





 IgM titers were found by serum ELISA on weeks 2, 4, 9 and 13 to determine the potential 
for IgM overload, associated with hapten immunization65, 66, among each adjuvant group (Figure 
2C). The IgM titers for all groups each week were significantly lower than the IgG titers by an 
over 102 order of magnitude. The 13a and 13a +TMX groups showed similar trends where IgM 
titers stayed relatively constant between weeks 2 and 4 then fell post first boost and rose again by 
termination. The 13a +NKT group on the other hand, peaked at week 4 and subsequently fell 
following first boost, maintaining this low level through termination. While both the 13a and 13a 
+TMX groups showed IgM levels similar to each other throughout the immunization schedule, the 
13a +NKT group had significantly lower IgM levels. None of the groups had high enough IgM 
levels relative to IgG levels to support the notion of IgM overload. Despite this, the very low IgM 
titers in the 13a +NKT group still support its use in ensuing experiments. 
To provide evidence that affinity maturation had occurred, an IgG subclass analysis was 
performed by serum ELISA at week 9 (Figure 2D). BALB/c mice are capable of producing four 
IgG subclasses: IgG1, IgG2a, IgG2b, IgG3.68 Each subclass has its own unique properties and path 
to development. Subclass switching from IgM to IgG1, IgG2a and IgG2b can occur through CD4+ 
T cell dependent cytokine release of IL-4, INF-𝛾 and TGF-β respectively.69 Since affinity 
maturation is associated with this cytokine induced class switching, high IgG1 and IgG2a levels 
by week 9 in all groups shows T cell dependent affinity maturation regardless of adjuvant. This 
result in the non-adjuvated 13a group is indicative of the self-adjuvating properties of VLPs which 
are able to promote T cell priming through activation of TLR7/8 by packed mRNA.5 Studies have 
also shown in mice that IgG3 is formed mainly through a T cell independent process and is 
associated with early infection.69 The low levels of IgG3 in all groups shows a highly developed 





mediated switching.70 Studies into the level of affinity maturation of each subclass in both mice 
and humans have shown that IgG1 tends to be the most affinity matured subclass since on average 
it has by far the most IGHV gene mutations.71 While a high IgG2a response in each group is 
expected as it is associated with viral infection6, it is notable that the 13a +NKT group is the only 
one that has higher IgG1 levels than IgG2a. This supports the literature which reports that NKT 
agonist adjuvants promote affinity mediated switching from IgG3 to IgG1.67 The high levels of 
IgG1 and IgG2a, along with low levels of IgG3 at week 9 in each group supports the hypothesis 
that adequate affinity maturation has occurred to produce high affinity antibodies by week 9. 
Additionally, since IgG1 antibodies tend to have the highest affinity of the four subclasses, this 
data supports the use of NKT in subsequent experiments.  
 Since the immunizations for each group were performed in triplicate, at week 13 the mouse 
with the highest antigen specific titer from each group was selected for hybridoma development. 
Splenectomies were performed and the B cells perfused from the spleens. The number of B cells 
resulting from the perfusion were within normal range for all three groups (Figure 2E). The B cells 
were then electrofused with myeloma by the Immunodiagnostics Development team at the CDC. 
The number of IgG producing clones that resulted from the fusion was found to be significantly 
higher in the 13a +TMX mouse (46) than the 13a (4) and 13a +NKT (6) mice. Despite this, none 
of clones in this population were found to be antigen specific. On the other hand, the 13a 
population resulted in one antigen specific clone and the 13a +NKT population resulted in 2 
antigen specific clones generated. The 13a +NKT clone population therefore had the highest 
antigen specificity rate of over 33%.  
 The results from this optimization experiment support a shorter 5-8-week immunization 





well as affinity maturation (Figure 2B,C&D). The multiple boosts aide in B cell differentiation 
and maturation. Since many of the results from the adjuvant groups were not significantly different 
from one another and a low sample size was used, no definitive conclusions can be made. 
Nevertheless, we chose to move forward with the NKT agonist as it resulted in the highest total 
IgG and IgG1 titers, the lowest IgM titers, and the most antigen specific clones.  
 
5.1.3. All Derivative Immunizations 
 Vaccines were created for each of the eight fentanyl derivative targets by attaching the 
molecules to PP7 VLPs using the CuAAC reaction. The antigen density after installment on the 
VLP particles ranged from 100-228 fentanyl molecules per VLP depending on the derivative 
(Appendix A).  This was an adequate number for proper multivalent display and no correlation 
was found between antigen density and ultimate serum antibody titers (Appendix A). Conjugates 
were purified by column chromatography and concentrated by centrifugation. Protein 
concentrations were determined by Bradford assay and characterization was confirmed by DLS, 
FPLC and LCMS (Appendix A).  
 After synthesis the vaccines were immunized into BALB/c mice at week 0 along with the 
NKT agonist with 4-7 replicate mice in each group. The mice were boosted at weeks 2 and 4 as 
well as 3 days prior to termination which ranged from week 5-8 (Figure 3A). Mice were bled at 
one-week intervals and serum ELISAs were conducted to determined antigen specific IgM and 
IgG binding over the course of the immunization schedule. Similar to the trend shown by the 13a 
+NKT group in the optimization experiment, IgM titers were extremely low compared to IgG titers 





highest week 3 IgM titers, also had very high IgG titers (>104) by week 3. This is a positive sign 
that IgM overload due to the hapten vaccine was not occurring.  
Similarly to the optimization experiment, most vaccines resulted in high titers (>104) only 
1 to 2 weeks post primary immunization (Figure 3B). This was not the case for norcarfentanil-1 
and norcarfentanil-2. As previously hypothesized, both these immunogens resulted in a lower 
humoral immune response that the other derivatives (Figure 3C). Both norcarfentanil-1 and 
norcarfentanil-2 were able to steadily increase titers over the course of the immunization schedule.  
 
Figure 3. Immunogenicity of eight fentanyl derivative VLP-conjugate vaccines. (A) Immunization schedule of 
BALB/c mice with fentanyl derivative VLP vaccines and NKT agonsit. (B) Anti-cognate antigen IgM titers determined 
by ELISA. (C) Anti-cognate antigen IgG titers over time determined by ELISA. Means show by line and individual 





Norcarfentanil-2 mice were able to climb to a titer of nearly 105 which is on the same order of 
magnitude as the other vaccines. Norcarfentanil-1 immunized mice, however, were only able to 
an average titer of 104, about one order of magnitude smaller than the rest, by termination. These 
results show that the vaccine for each derivative was able to produce strong antigen specific 
humoral immune response, a promising step towards mAb development. 
 
5.1.4. Hybridoma Fusion and Clone Characterization 
 At week 5-8 depending on immunization schedule the mouse with the highest antigen 
specific titer was from each of the vaccine groups was selected for hybridoma development. 
Splenectomies were performed and the B cells perfused from the spleens. The number of B cells 
resulting from the perfusion were within normal range for all fusions (Appendix A). The B cells 













































































Clones Picked Antigen Specific Clones VLP Cross Reactive
Figure 4. Analysis of fentanyl hybridoma fusion statistics. Number of IgG clones that resulted from hybridoma 
fusion (blue), number of antigen specific clones from that population (yellow), and number of antigen specific 





The hybridoma were screened for IgG production (clone picked), antigen specificity and 
the antigen specific clones for VLP cross reactivity (Figure 4). The number of IgG producing 
clones that resulted from the fusion ranged from 152 (carfentanil) to 1316 (Norcarfentanil-1). The 
number of antigen specific clones ranged from 11 (carfentanil) to 299 (fentanyl). All groups 
resulted in significantly more positive clones with the optimized immunization schedule than the 
13-week schedule. Only fentanyl and norcarfentanyl-1 had a large number of VLP cross reactive 
clones of those shown to be antigen specific with 62 and 48 respectively. VLP cross reactivity is 
an indicator of hapten-peptide presentation on MHC II. The norcarfentanil-1 and norcarfentanil-2 
clones were dropped from further experimentation due to a low probability of high affinity 
antibodies as previously discussed. 
Figure 5. Subclass determination of fentanyl derivative mAb supernatant. IgG subclass of antigen specific clones 





 An IgG subclass analysis was run by supernatant ELISA to determine the subclass of 
antigen specific clones (Figure 5). Cloned were labeled as unassigned if multiple subclasses were 
found within a single clonal line’s supernatant. This was found in clones within the fentanyl, 4-
MeO-fentanyl and acetyl αMe-fentanyl groups. All groups had mAbs with both IgG1 and IgG2a 
subclasses. This is consistent with the 13a +NKT serum results from the optimization experiment, 
in which these subclasses had the highest titers. IgG2b and IgG3 mAbs also resulted from the 4-
MeO-fentanyl and 3Me-fentanyl immunizations respectively. The high percent of IgG1 subclasses 
across all derivatives is indicative of the success of the vaccine platform for hapten immunizations. 
 
5.1.5. MAb Functionality 
  The supernatant from clones that were positive for binding to their cognate antigen were 
then tested by ELISA for cross-reactivity to the other seven derivatives (Appendix A). The 
absorbances were normalized to binding against their respective immunogen as a percentage 
across all 180 mAbs tested with 100% representing the highest absorbance and strongest binder, 
and 0% representing the lowest absorbance and no binding. The binding patterns of each mAb 
were compared and 14 unique binding patterns were found. The mAbs with the highest percent 
binding to their positive matches and lowest percent binding to their negative matches were chosen 
to represent each binding pattern group (Figure 6). In this way, we hope to capture representative 
mAbs capable of distinguishing between these compounds in immunoassays. 
 Interestingly, all of the mAbs that showed the most distinct binding for each binding pattern 
group were derived from only three immunizations: acetyl αMe-fentanyl (αMe), fentanyl (82), 
carfentanil (CF1). αMe-10H2 was the only mAb found to positively differentiate one derivative 





fentanyl from the fentanyl molecule as well as from the carfentanil which it shares a linker location 
with, makes it highly likely that the α-methyl functional group on the ethylbenzene plays a 
significant role in the epitope binding as that is the only differentiating structure. Unsurprisingly, 
the mAbs did not bind norcarfentanil-1 or norcarfentanil-2 well since these metabolites have far 
fewer functional groups to bind than the other derivatives. In fact, the only mAb capable of binding 
either was αMe-8C12 which only bound norcarfentnail-2. The ability of this mAb to bind 
norcarfentanil-2, but not norcarfentanil-1 could be due to the presentation of acetyl αMe-fentanyl 
vaccine from which the mAb was derived, which has a “head” linker location similar to 
norcarfentanil-2 as opposed to norcarfentanil-1 which has a “tail” linker location. The other 
possible explanation for this is that the mAb binding relies heavily on the amide functional group, 
which is not present on norcarfentanil-1. Another interesting binding pattern is that of 82-1B1. 
This mAb did not show binding to carfentanil but did to acetyl αMe-fentanyl. A possible 
explanation for this is that the region between the piperidine and anilide plays an important role in 
the mAb’s binding, and the CO2Me group interferes with this. This is consistent with the mAb’s 
lack of binding to norcarfentanil-1 and norcarfentanil-2, which both also have the CO2Me group. 
Figure 6. Cross reactivity of mAbs to eight fentanyl derivatives. Percent binding of 14 mAbs representing unique 





The binding pattern of CF1-3G1 is interesting in that it is most likely not due to specificity to 
acetyl αMe-fentanyl and carfentanil, but rather due to limitations in the ELISA design which places 
a PEG linker on the alkyl benzene of the other four non-metabolite derivatives, thereby blocking 
a probable binding site of the mAb. The various binding patterns of these mAbs once tested against 
unmodified fentanyl analogs (not possible in our lab) could shed further light on the important 
functional groups for binding corresponding and help inform future vaccine design for epitope 
targeting.  
 
Of the 14 mAbs selected for their unique binding pattern, only 6 (82-4C6, αMe-8A11, 82-
4A4, CF1-1B1, αMe-10H2 and αMe-8C12) are needed to positively distinguish each derivative 
from the others excluding norcarfentanil-1 (Figure 7). The derivatives were first able to be split 
into two groups based on positive or negative binding to 82-4C6. From there these two groups 
were each able to be split again based on positive or negative binding to αMe-8A11. The resulting 
groups of two derivatives were then able to be distinguished using four additional mAbs: 13a 
fentanyl from 4-MeO-Bu fentanyl with CF1-1B1, norcarfentanil-1 from norcarfentanil-2 with 
αMe-8C12, carfentanil from acetyl αMe-fentanyl with αMe-10H2, and fentanyl from 3Me-
Figure 7. Distinguishing derivatives using mAbs. Differential binding of six mAbs to the eight derivatives needed 





fentanyl with 82-4A4. Though validation of binding using unmodified derivatives must still be 
conducted to ensure no linker effect on the ELISA cross reactivity results, this data shows that 
together these six mAbs can be used as a diagnostic tool to differentiate among these eight 
derivatives. 
 
The linker location effect on both the immunology of molecule display by the VLP and the 
ELISA results from use of the PEG linker was further analyzed. The similarity in the percent 
binding between the six non-metabolite derivatives to the 14 mAbs with different binding patters 
was determined (Figure 8A). There is a clear distinction between binding of the derivatives with 
“head” linkers (carfentanil and acetyl αMe-fentanyl) and the other four with “tail” linkers. This 
distinction was summarized to show the average percent binding similarity of all “tail” linker 
derivatives compared to “tail” linker derivatives, “head” linker derivatives compared to “head” 
linker derivatives, and finally “tail” linker derivatives compared to “head” linker derivatives 
(Figure 8B). A Kruskal-Wallis test with Dunn’s multiple comparison was run to determine if the 
Figure 8. Analysis of linker location effect on fentanyl mAbs. (A) Average percent binding similarity between each 
derivative determined by subtracting the average difference in percent binding of each derivative comparison across 
the 14 mAbs with different binding patterns from 100%. (B) Average percent binding similarity averaged across all 





differences between each group were significant and the results showed the “Tail vs Tail” group 
was significantly greater in average percent binding similarity than the “Tail vs Head” group. The 
“Head vs Head” group was not significantly greater, however since it actually had a higher average 
percent binding similarity than even the “Tail vs Tail” group this can be attributed to the fact that 
there was only one value within this group. 
This difference in binding similarity can be attributed to two factors: the epitope targeting 
of the antibodies due to display orientation of the molecule on the VLP, and the location of the 
PEG linker on the molecules for ELISA analysis most likely blocks epitopes. The epitope targeting 
is advantageous to the study because it shows that by adjusting linker location, we are able to better 
target differentiating functional groups. The PEG linker on the molecules for ELISA analysis, 
however, complicates these results. It is likely that the mAbs such as CF1-3G1 require the 
alkylbenzene functional group for binding. This means this mAb is probably also capable of 
binding all six derivatives, the ELISA results just show otherwise because the PEG linker sterically 
inhibits this binding on the tail linker molecules. This shows limitations in our analytical strategy 
for mAb cross reactivity between molecules with different linker locations.  
Figure 9. Cross reactivity of fentanyl 13a mAbs to naloxone. Effect of introduction of varying concentrations of 






In addition to use in diagnostics, anti-fentanyl mAbs also have the potential to be 
humanized and used as overdose therapeutics as previously described by Smith et al.48 In this 
model naloxone would be used as the fast acting treatment and mAbs has the longer term treatment 
after admission to a hospital. This makes it important that the mAbs have no cross reactivity to the 
naloxone that could dampen both treatments effects. To ensure this we analyzed the competitive 
binding ability between naloxone and fentanyl-13a to six anti-13a mAbs (Figure 9). Decreasing 
concentrations of naloxone beginning at nearly 1 M (at the maximum solubility concentration) 
were mixed with the biotinylated fentanyl 13a and the relative binding was determined. The results 
showed that naloxone did not inhibit mAb binding to fentanyl-13a, nor did the naloxone bind the 
mAb to any appreciable amount. This shows that when used as a combination therapy for overdose 
victims these two treatments could be used in tandem with no interference. 
 
5.1.6. Conclusions and Future Experimentation 
 Here, we demonstrated that a VLP conjugate vaccine platform can be used to develop 
mAbs for certain fentanyl derivative. We found the optimal vaccine strategy is a short 5-8-week 
immunization schedule using an NKT agonist as the adjuvant. Under these conditions we were 
able to elicit a high titer polyclonal antibody response against each of the derivatives. We were 
then able to isolate 14 mAbs with unique binding patters to the eight fentanyl molecules. Together 
6 of these mAbs can be used to positively differentiate between all fentanyl molecules tested except 
norcarfentanyl-1. One mAb (αMe-10H2) was able to exclusively bind acetyl αMe-fentanyl, 
allowing it to differentiate this derivative from all others tested. We also demonstrated in an early 





treatment, which can be further explored how by measuring rate of fentanyl clearance in mice in 
future experiments. 
 To validate the differential binding of these mAbs to the fentanyl derivatives, we will have 
to analyze their binding to the unmodified fentanyl derivatives as the linkers have the potential to 
limit binding in our current analytical method. It is also important to ensure these antibody-
molecule interactions are high affinity. To do this, binding affinities will be determined by BLI. 
The chosen mAbs from based on results from these experiments will be sequenced. Lastly, to move 
forward with potential therapeutic use, the chosen mAbs would need to be tested to ensure they do 



















5.2 SARS-CoV-2 Peptides 
5.2.1. Peptide Selection and Structures 
 We chose to target six different SARS-CoV-2 peptides based on known neutralizing 
activity of the epitopes and probability of binding MHC II. Peptides 6 and 9, each part of the RBD 
of the spike protein, were cloned into the PP7 plasmids as C terminal extensions (Figure 10). 
Peptides 16 and 17, part of the C terminal domain and N terminal domain respectively, were also 
genetically conjugated as C terminal extensions of the PP7 plasmid. An RBM peptide containing 
4 out of 6 RBD/ACE2 contact residues52 (RBM) and the spike protein fusion peptide (FP) were 




Figure 10. Structure of SARS-CoV-2 peptides for vaccine conjugation. (A) Top view of cartoon SARS-CoV-
2 spike protein (6vxx) with sphere peptides 6 (red), 9 (blue), 16 (green) and 17 (purple). (B) Side view of cartoon 
SARS-CoV-2 spike protein with sphere peptides RBM (light blue) and FP (pink). (C) Table of each peptide with 






5.2.2. Peptide Immunizations 
 The immunizations were split into three groups with different immunization schedules. All 
groups were first given a primary immunization with the PP7-peptide conjugate vaccine followed 
by three boosts with either an mFc tagged RBD or the ectodomain spike homotrimer glycoprotein. 
We hypothesized that the primary dose would target the immune response toward the peptide of 
interest and the boosts would select for those that also bound the peptide in its correct confirmation. 
The first group received either peptide 6 conjugate vaccine (PP7-covid-6) or the peptide 
16 conjugate vaccine (PP7-covid-16). They were both given a primary immunization with the 
conjugate vaccine followed by whole protein boosts at weeks 2, 3, and 4 (Figure 11A). The anti-
ecto titer remained low for the PP7-covid-6 mice at week 3 but increased to almost 103 by 
termination (Figure 11B). Though lower than expected, the titer was considered adequate for 
scheduled splenectomy and B cell extraction 3 days following the final boost. The PP7-covid-16 
mice anti-ecto titers steadily increased to a robust final terminal titer (>104). 
 The second group received one of two conjugate vaccine cocktails for primary 
immunization. This strategy allows for targeting of multiple epitopes in a single vaccination. 
Cocktail 1 contained an equal mixture of PP7-covid-6, PP7-covid-16 and PP7-covid-17. Cocktail 
2 contained an equal mixture of PP7-covid-6 and PP7-covid-9. All of these conjugated were made 
through genetic modification of the PP7 plasmid (Figure 10). Following primary immunization, 
all mice were boosted with whole protein RBD on weeks 2, 4, and 8 (Figure 11A). The Cocktail 1 
mice, similar to the PP7-covid-6 mice showed low anti-ecto titers through week 4, then increased 
to >104 by termination (Figure 11B). The cocktail 2 mice, similar to the PP7-covid-16 mice, 









The third group received primary immunizations with either the RBM or FP peptide that 
were both presented by covalent chemical modification of the PP7 particles post assembly. 
Following primary immunization, the PP7-RBM mice were boosted with whole protein RBD at 
weeks 2, 5, and 7 and the PP7-FP mice at weeks 3, 5, and 7 (Figure 11A). Mice from both 
immunization types showed low titers at week 4.5 which then increased to about 104 by week 6 
and maintained those titers at termination. This is a similar trend to those showed by the PP7-
covid-6 and Cocktail 1 immunizations.  
 We hypothesized that the reason for low anti-ecto titers post immunization with the VLP-
peptide, but a large increase after immunization with whole protein could be a result of one of two 
Figure 11. Immunogenicity of SARS-CoV-2 peptide VLP-conjugate vaccines. (A) Immunization schedule for 
each vaccine group PP7-covid-6 (blue), PP7-covid-16 (purple), Cocktail 1 (green), Cocktail 2 (orange), PP7-RBM 
(light blue), PP7-FP (purple). (B) Anti-ecto titer over time of genetically modified peptide groups determined by 
ELISA. (C) Anti-ecto titer over time of cocktail peptide groups determined by ELISA. (D) Anti-ecto titer over time 





immunological factors. First, the linear display of the peptides on the PP7 could be inadequate to 
create an immune response against the peptides in their confirmation as part of the whole 
ectodomain. This hypothesis would mean we were unsuccessful at directing the immune response 
to that peptide and the later increase in titer was due solely to an untargeted immune response at 
the whole protein. The other explanation for the trend shown is that the VLP-peptides were able 
to initiate the targeted immune response, but that proliferation of those B cells did not occur until 
introduction of the whole protein. This hypothesis would support the conclusion that we were able 
to direct the immune response towards the peptide of interest. To further assess this heterologous 
prime-boost strategy we designed an experiment targeting mutant peptides described in the Mutant 
Peptide section of this chapter.  
 
5.2.3. Hybridoma Fusion and Clone Characterization 
Though we could not validate that the polyclonal mouse immune response was directed 
towards the peptides of interest we chose to move forward with hybridoma development. 
Splenectomies were performed 3 days post final boost and the B cells perfused from the spleens. 
The number of B cells resulting from the perfusion were within normal range for all fusions (Figure 
12). The B cells were then electrofused with myeloma by the Immunodiagnostics Development 
team at CDC. The IgG producing hybridoma were then picked and screened for binding to the 
whole spike ectodomain. From the first group of immunizations, PP7-covid-6 and PP7-covid-16 
resulted in 192 and 2 clones respectively that bound the ectodomain (Figure 12A). From the second 
group of immunization, Cocktail 1 and Cocktail 2 resulted in 71 and 13 clones respectively that 
bound the ectodomain (Figure 12B). From the third group, PP7-RBM and PP7-FP resulted in 6 








The data analysis is limited by the analytical methods of epitope mapping and therefore 
conclusions about mechanisms cannot be made between immunization groups. Nevertheless, it is 
notable that within the first two groups in which each immunogen showed different trends in anti-
ecto titer development, the immunogen with lower post primary immunization titers (PP7-covid-
6 and Cocktail 1) resulted in more spike reactive clones than its partner immunogen that followed 
the same schedule. This would make the hypothesis that the linear peptide display was unable to 
produce a directed B cell response that could be further proliferated with the whole protein 
unlikely. This is because a later introduction of the ecto, especially in the case of the first 
immunization group which saw whole protein for the first time only two weeks before termination, 
Figure 12. Statistics from SARS-CoV-2 peptide fusions. Number of cells perfused from spleens per mL (black), 
number of cells still alive by time of experiment per mL (yellow), total number of B cells perfused from spleens (blue), 





would likely result in fewer anti-ecto IgG as IgG response takes time to mount. These results are 
promising sign that the VLP-peptide primary immunization did direct an initial peptide specific 
immune response.  
 
  
Though it is difficult to determine exact epitope targeting of antibodies without a cryo-EM 
structure of their binding, the breakdown of our mAbs binding to the S1 subunit versus the entire 
ectodomain does provide some insights (Figure 13). The S1 subunit (residues 14-685)33 contains 
peptides 6, 9, 17, RBM, and part of 16. The FP is the only peptide tested that lies completely 
outside of the S1 subunit.72 We analyzed the binding of each mAb to both the whole ectodomain 
and the S1 subunit by ELISA to determine if it had a preference for one or bound both. The dual 
preference mAbs likely bind somewhere on the S1 subunit since this is also on the ectodomain. 
Those with an ectodomain preference likely bind outside of the S1 subunit.  
The FP has by far the highest percentage of ectodomain preferred mAbs, however this trend 
could be a result of this immunization receiving whole ectodomain boosts rather that S1 and RBD 
boosts rather than true epitope targeting. The ectodomain preferred mAbs from the PP7-covid-6 
and Cocktail 2 are surprising considering neither none of the immunizations these mAbs are 
derived from used any protein outside the S1 subunit. This data does not provide information on 
exact epitope targeting; however, it does narrow down the likely binding domains of each mAb.  
Figure 13. Binding preference of SARS-CoV-2 peptide mAbs preference. Breakdown of binding preference 








 In order to be used in diagnostics or as biological reagents, it is important that the mAbs 
not only bind the antigen of interest but also bind it with a high affinity. The Immunodiagnostics 
Development team at the CDC determined the binding affinity of chosen clones by BLI (Figure 
14). Multiple mAbs were found to have exceptional nanomolar and sub-nanomolar affinities for 
the ectodomain, ideal for use in diagnostics. Multiple mAbs from the Cocktail 1 and Cocktail 2 
immunizations as well as one from the PP7-covid-6 immunization had picomolar binding 
affinities, however this is likely below the instruments limit of detection so exact affinities cannot 
be determined. This confirms that the immunization schedule was successful in eliciting a humoral 




Figure 14. Binding affinities of SARS-CoV-2 peptide mAbs. binding affinities depicted as 1/Kads for mAbs 






5.2.4. Mutant Peptides 
 Based on the early successes with peptide targeting with known neutralizing peptides on 
the spike protein, we also began experiments to try to target high profile mutations. Our first target 
was the Y453F mutation in the spike protein RBD. We designed a heterologous prime-boost 
strategy to determine the best immunization strategy for peptide targeting. The VLP-peptide 
vaccines were made with PP7 using the CuAAC reaction to attach either the wild type or mutant 
linear peptide. The two immunization strategies were a) prime with wild type or mutant VLP-
peptide and boost twice with wild type or mutant whole RBD protein or b) prime with wild type 
or mutant whole RBD protein and boost twice with wild type or mutant VLP-peptide (Figure 15A). 
For each schedule, 5 mice were immunized with prime and boosts on weeks 0, 2, 4 and the mice 
were terminated at week 7 for hybridoma production. The serum was monitored throughout for 
anti-RBD and anti-peptide IgG response by ELISA. 
 Both the wild type and mutant immunizations showed similar trends for the two different 
schedules. For schedule a, both immunizations initially showed a sharp increase in anti-peptide 
response at week 2 to a titer of nearly 104 followed by a steady decline (Figure 15B, 15C). The 
initial anti-RBD response for each was low before receiving whole protein boosts at week 2 and 
then steadily increased to a titer of about 105. The decrease in anti-peptide response corresponding 
to the increase in RBD response could indicate that the initial peptide immunization was not 
enough to direct the immune response post RBD immunization towards the peptide. As a result, 
the immune system seems to have been overwhelmed by the immunogenicity of the RBD creating 
a response to many epitopes on the protein. This especially seems to be true with the 1a 
immunization as the week 7 peptide titer dropped nearly to pre-immunization levels. Even in the 








Figure 15. Immunogenicity of SARS-CoV-2 mutant peptide VLP-conjugate vaccines. (A) Immunization schedule 
for each of the four immunization groups each containing 5 mice. (B) Anti-RBDwt (yellow) and anti-peptidewt (dark 
yellow) titers over time for 1a schedule determined by ELISA. (C) Anti-RBDwt (red) and anti-peptidewt (dark red) 
titers over time for 1b schedule determined by ELISA. (D) Anti-RBDY453F (purple) and anti-peptideY453F (dark purple) 
titers over time for 2a schedule determined by ELISA. (E) Anti-RBDY453F (blue) and anti-peptideY453F (dark blue) titers 






 The schedule B immunizations for both the wild type and mutant showed a far better linear 
peptide response over time than the schedule A immunizations (Figure 15D, 15E). They both 
showed a spike in anti-ecto titers at week 2 and maintained robust titers throughout. The anti-
peptide response for each increased steadily to final titers at week 7 ten times less than RBD 
response, much greater than those seen in group A immunizations. This suggests that a far higher 
percentage of the humoral immune response from schedule b was directed towards the peptide of 
interest, increasing the probability of finding a mutant or wild type selective mAb.  
At week 7 the mice with the highest antigen specific titer was from each of the vaccine 
groups were selected for hybridoma development. Splenectomies were performed and the B cells 
perfused from the spleens. The number of B cells resulting from the perfusion were within normal 
range for all fusions (APPENDIX B). The B cells were then electrofused with myeloma by the 
ImmunoDiagnostics team at the CDC to produce hybridoma. 
The resultant clones were all screened for wild type and mutant RBD and peptide response 
by ELISA (APPENDIX B). Very few mAbs were reactive to the linear peptides and none showed 
reactivity to both the linear peptides and the RBD. However, just because the mAb does not bind 
the linear peptide does not mean it does not bind that epitope, as conformation of the peptide could 
play a significant role in binding ability. When analyzing solely the total number of RBD reactive 
clones the two immunization strategies seem to have opposite trends depending on immunization 
with the wild type or the mutant (Figure 16). The 1b and 2a schedules resulted in by far the highest 
number of mAbs reactive to both wild type and mutant RBD. This is surprising and most likely 
not due to any mechanistic differences between the effects of the wild type and mutant peptides.  
  Despite the surprising results in total number of RBD reactive mAbs, there is a clear 





(Figure 16). While the two A groups had no selective mAbs, the 1b and 2b groups had a total of 8 
wild type RBD and 4 mutant RBD selective mAbs. Since the Y453F mutation removes a hydroxyl 
group that had the potential for an additional hydrogen bond, it follows that more mAbs would be 
selective for the wild type over the mutant RBD. This does make it very surprising, however, that 
an mAb derived from the 1B immunization which was only exposed to the wild type peptide and 
RBD would be selective for the mutant RBD. This result will need to be confirmed by BLI binding 
to each RBD. Since the goal of this experiment was to produce clones selective to one RBD over 
the other, the schedule in which the mice were primed with RBD and boosted with VLP-peptide 
was clearly more effective. This strategy suggests that the prime selects for germline B cells that 




Figure 16. Binding preference of SARS-CoV-2 mutant peptide mAbs. Binding preference of mAbs from each 
immunization group to either wild type RBD (yellow), Y453F RBD (purple) or both (green) determined by ELISA. 
 
































5.2.5. Conclusions and Future Experimentation 
 These studies show that the VLP conjugate vaccine platform has the potential to be used 
in peptide epitope targeting. Though we do not yet have conclusive evidence to prove we 
successfully developed mAbs against our peptides of interest, the data shows a lot of promising 
early signs we did. The results from the mutant peptide experiment showed we were able direct 
the immune response towards the peptide of interest using a heterologous prime-boost strategy in 
which we primed with whole protein RBD and boosted with VLP-peptide. Using this strategy, we 
were able to develop mAbs with specificity towards either the wild type or Y453F mutant RBD. 
We were also able to produce nanomolar and sub nanomolar affinity mAbs which is important for 
their use as diagnostics and biological reagents.  
 To validate the epitope targeted by the most promising mAbs, cryo-EM structures of the 
mAbs binding the ectodomain are needed. This would provide conclusive evidence that were able 
to target specific peptides for mAb discovery. Additionally, antibody affinity is needed. To 
validate and build on this work we are in the process of once again trying the two different 
heterologous prime-boost strategies with different high-profile mutants including the K417N, 












5.3. α-Amanitin and Microcystin-LR Toxins 







 Both the microcystin LR and α-amanitin were conjugated to Qβ virus-like particles by first 
installing short alkyne linkers labeled in light grey (Figure 17). The functional groups labeled in 
blue show variable positions that distinguish each toxin from their various congeners. Microcystin 
LR was functionalized with a alkyne bioconjugation linkers. The lysine residues on the Qβ 
particles were functionalized with azide groups using NHS ester chemistry. The linker labeled 
toxins were then conjugated to the Qβ particles using copper-catalyzed azide-alkyne cycloaddition 
to create the vaccines. This allowed for multivalent display of the toxins on the surface of the VLP 




Figure 17. Structure of α-amanitin and microcystin for vaccine conjugates. The molecular structures of each 






5.3.2. Toxin Immunizations 
 Both the microcystin LR and α-amanitin conjugate vaccines were administered at weeks 
0, 2, 4 and 3 days before termination at week 8 (Figure 18A). Each immunization group consisted 
of four mice. The mean serum titers for each group were determined over time. The doses did turn 
out to be toxic to some of the mice as shown by their weights. This, however, did not seem to 
impact their overall immune response. The anti-microcystin LR immediately jumped to greater 
than 104 and remained there throughout the course of the immunization schedule (Figure 18B). 
The anti-α-amanitin titers steadily increased throughout the course of the immunization schedule 
to a final titer at week 8 greater than 104 (Figure 18C). These high titers were optimal for spleen 








Figure 18 Immunogenicity of α-amanitin and microcystin LR VLP conjugate vaccines. (A) Immunization 
schedule for both α-amanitin and microcystin LR vaccines. (B) Anti-microcystin LR IgG titers over time 






5.3.3. Hybridoma Fusion and Clone Characterization 
At week 8 the two mice with the highest antigen specific titer was from each of the vaccine 
groups were selected for hybridoma development. Splenectomies were performed and the B cells 
perfused from the spleens. The number of B cells resulting from the perfusion were within normal 







IgG producing hybridoma were picked from each fusion and their binding ability to their 
cognate antigen was determined by ELISA (Figure 19). A total of 645 IgG producing clones were 
picked from the from the microcystin LR immunizations and 34 of these were found to bind 
microcystin LR. From the α-amanitin immunizations 903 clones were picked and of these 42 were 
positive for α-amanitin binding. The low percentage of IgG producing clones that bind to their 
cognate antigen in both groups is similar to those seen with the fentanyl targets and significantly 
lower than those seen with the peptide targets despite similar serum titers. This could be a result 
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Figure 19. Statistics from α-amanitin and microcystin LR fusions. Statistics from toxin fusions with total 
number of B cells isolated from splenectomies (black), total number of IgG producing hybridoma picked (blue) 













There are three commonly found microcystin variants that have the potential to 
contaminate water supplies microcystin LR, microcystin LY, and microcystin RR (Figure 20A, B, 
C). Overall, the structures are very similar aside from functional group changes in two locations 
labeled in blue, making broad spectrum mAbs far more easily attainable than derivative selective 
clones. BLI was performed by CDC on each of the microcystin LR immunization derived mAbs 
to test for binding affinity to each variant (Figure 20B). A commercially available mAb was also 
analyzed for comparison. The commercial mAb had broad spectrum sub nanomolar binding 
Figure 20. Analysis of microcystin LR mAbs’ binding preference and affinities. (A) structure of microcystin 
LR. (B) structure of microcystin LY. (C) structure of microcystin RR. (D) Binding affinities shown as 1/Kads of 16 







affinity. We were able to isolate six broad spectrum clones (MRC2-8E3, MRC2-8H5, MRC2-
8F12, MRC2-9G5, MRC2-9A1, and MRC2-10D4) with sub picomolar binding affinities. Since 
they bind each variant with an equal affinity, their most important binding epitopes probably rely 
on the conserved regions between each of the molecules. The better binding affinity of these clones 
means they could be used to create a more sensitive diagnostic field test.  
We also isolated three mAbs (MRC2-8G6, MRC2-8E4, and MRC2-9D11) that bind 
microcystin LR with a higher affinity than microcystin LY or microcystin RR. This indicates that 
both the isobutyl and guanidino groups on microcystin LR play an important role in binding for 
each mAb that the substitutions on microcystin LY or microcystin RR interfere with. One mAb 
(MRC2-8G7) had a higher affinity for both microcystin LR and microcystin RR than microcystin 
LY. This most likely indicates that the guanidino group on microcystin LR and microcystin RR 
plays an important role in MRC2-8G7 mAb binding that the substitution on microcystin LY 
interferes with. One mAb (MCR2-9F11) had a higher affinity for microcystin LY than microcystin 
LR and microcystin RR. This indicates that both the isobutyl and phenol groups on microcystin 
LY play an important role in MCR2-9F11 binding the substitutions on microcystin LR and 
microcystin RR interferes with. These derivative selective mAbs could be used to help in 
diagnostic differentiation between the three derivatives.  
 
 
5.3.4. Conclusions and Future Experimentation 
 In this study, we were able to successfully create an immune response against toxins 
microcystin LR and α-amanitin using a VLP conjugate vaccine platform. We were able to generate 
robust antigen-specific IgG titers for both constructs. We were able to isolate 34 clones producing 





α-amanitin. Of the clones that bound microcystin LR we were able to identify six with sub 
picomolar dissociation constants for all three microcystin variants which is orders of magnitude 
higher affinity than the current commercially available mAbs. We were also able to identify three 
mAbs with microcystin LR selectivity, one mAb with microcystin LR and microcystin RR 
selectivity, and one mAb with microcystin LY selectivity. There derivative selective mAbs have 
the potential to be used in diagnostics for variant differentiation. The next steps in this work will 
include sequencing of all the high affinity broad spectrum and derivative-selective mAbs. With 
this data we can determine if some of these mAbs with similar binding patterns and affinities also 

























 This thesis displays the potential for VLP conjugate vaccines to be used with a variety of 
immunization strategies in order to create mouse humoral immune responses against an array of 
target molecules ideal for mAb development. First, we were able to create an optimized 
immunization strategy using PBS-57, an NKT agonist adjuvant, and VLP-fentanyl vaccines to 
produce high IgG titers against eight fentanyl derivatives. We then used the B cells derived from 
these immunizations to produce hybridoma clonal cell lines capable of producing mAbs with 14 
unique binding patterns to these fentanyl derivatives. One of these mAbs was even capable of 
selectively binding only the acetyl αMe-fentanyl derivative. We then showed that 6 of these mAbs 
could be used in a diagnostic test to positively differentiate between each derivative. Lastly, we 
proved that these mAbs did not have any significant interaction with naloxone, meaning they could 
be used in a two-step combined treatment plan. These mAbs have the potential to be used as 
reagents, diagnostics, and therapeutics to help the current fentanyl epidemic in the United States. 
These results also confirm that mAbs can be derived from the robust IgG immune response elicited 
by hapten conjugate VLP vaccines. 
 Next, we used this method to develop mAbs for specific SARS-CoV-2 peptide targets. We 
were able to direct a polyclonal immune response towards certain epitopes using linear peptide 
display on the VLP while maintaining conformational specificity by using a heterologous prime-
boost strategy. We determined that the optimal sequence is to prime with whole protein RBD and 
boost with VLP-peptide. Using this strategy, we were able to isolate 8 mAbs that selectively bind 
the wild type RBD and 4 that selectively bind the Y453F mutant RBD. The mAbs that resulted 
from the neutralizing peptides are currently in use at CDC as reagents in biological assays, helping 





conjugate VLP vaccines in conjunction with whole protein immunizations can be used to create 
peptide specific and conformationally accurate mAbs.  
 Lastly, we used this method to develop high-affinity mAbs for the toxins α-amanitin and 
microcystin LR. Using conjugate Qβ vaccines we were able to produce high IgG titers against each 
of the toxins. Using B cells derived from these immunizations, we were able to isolate 34 
microcystin LR reactive hybridoma clonal cell lines and 42 α-amanitin reactive clonal cell lines. 
Of the microcystin LR mAbs we were able to find six with a higher affinity for all three microcystin 
variants than the commercially available mAbs. Additionally, we were able to identify three mAbs 
with microcystin LR selectivity, one mAb with microcystin LR and microcystin RR selectivity, 
and one mAb with microcystin LY selectivity. These mAbs can be used as broad spectrum or 
differentiating diagnostics for contamination with α-amanitin or the three microcystin variants. 
These results also confirm the ability of conjugate VLP vaccines to increase the immunogenicity 
while decreasing the toxicity of cyclic peptides. 
 Combined this data displays the versatility of the VLP vaccine platform in eliciting robust 
IgG immune responses against an array of targets. The success in developing mAbs using 
hybridoma technology from these VLP immunizations shows the conjugate VLP platform’s 
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APPENDIX A: PP7-wt fentanyl conjugate vaccines 
 









































Chemical Modification of PP7-Fentanyl Conjugate Vaccines 
 
Vaccine Fentanyl  








Fentanyl 0 274 228 0.1 
Furanyl Benzyl 
Fentanyl (13) 
n/a 431 135 0.06 
Norcarfentanil-1 
(NCF1) 
2,7 291 109 0.036 
Norcarfentanil-2 
(NCF2) 
2,7 329 192 0.066 
Carfentanil (CF1) 2 333 100 0.045 
4-MeO-Bu Fentanyl 4 333 190 0.088 
3Me Fentanyl 1 274 104 0.045 
𝜶-AcMe Fentanyl 6 274 142 0.058 
 
 





































































































APPENDIX B: SARS-CoV-2 peptide conjugate vaccines 
 


































































































































Binding Preference of Mutant Peptide Derived Clones to Ecto, RBD and Peptide 
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